The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer.
 
Kenichi Harano
Honoraria - AstraZeneca; Chugai Pharma; Eisai; MSD K.K; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - astrazeneca; Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi-Sankyo; Merck
 
Takehiro Nakao
No Relationships to Disclose
 
Shin Nishio
No Relationships to Disclose
 
Takahiro Katsuta
No Relationships to Disclose
 
Kazuto Tasaki
No Relationships to Disclose
 
Kazuhiro Takehara
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Ethicon/Johnson & Johnson; Kracie Pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Zeria Pharmaceutical
Research Funding - Chugai Pharma
 
Takanori Yokoyama
Honoraria - AstraZeneca Japan; Takeda
 
Hideki Furuya
No Relationships to Disclose
 
Kyoko Hongo
No Relationships to Disclose
 
Masatoshi Asano
No Relationships to Disclose
 
Takashi Ikeno
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Nihon Medi-Physics
 
Akihiro Sato
Honoraria - Astellas Pharma; AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Suguru Odajima
No Relationships to Disclose
 
Hiroshi Tanabe
No Relationships to Disclose
 
Tetsuro Taki
No Relationships to Disclose
 
Reiko Watanabe
No Relationships to Disclose
 
Genichiro Ishii
No Relationships to Disclose
 
Toru Mukohara
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Kirin; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Eisai; Micin
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Gilead Sciences (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst)